Product Highlight - Vizimpro

Active ingredient: Dacomitinib.

Indication: First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.

Dosage & Administration: 45 mg once daily until disease progression or unacceptable toxicity occurs.